ALSO IN THIS MONTH'S ISSUE

• Election Fallout: Can Divided Government Forge Bipartisan Solutions?

  As the election concludes, we still face new changes to healthcare policy, pharma price-controls, taxes, and a staggering debt.

• COVID-19 And Cell And Gene Sector: Contingency Planning For 2021 And Beyond

  Some of the brightest luminaries representing the sector’s various subsets all answer the same question: As a result of COVID-19, how have you and your team had to pivot to ensure continued success in 2021 and beyond?

• AI And Machine Learning Prepare Pharma For The Data Onslaught

  When I reached out to several clinical executives in my network for their thoughts on trends that will impact trials in the coming year, the two mentioned most frequently were AI and decentralized trials.

• What Do 10 Biopharma Finance Experts Expect for 2021?

  We invited 10 biopharmaceutical industry finance experts to provide their perspectives on everything from remote work, to supply chains, to the reshoring of U.S. biopharmaceutical manufacturing operations.

• Can Your CDMO Relationships Survive Another “Virtual” Year?

  Lori Hoffman, head of alliance management, Slayback Pharma; and Greg Birrer, quality head, Elusys Therapeutics, talk about how the pandemic has affected CDMOs.